Holen Sie sich die Stockscreener-App
26.95
2.00%
-0.55
Handel nachbörslich:
26.95
Schlusskurs vom Vortag:
$27.50
Offen:
$27.44
24-Stunden-Volumen:
747.84K
Relative Volume:
0.90
Marktkapitalisierung:
$1.76B
Einnahmen:
$10.00M
Nettoeinkommen (Verlust:
$-425.15M
KGV:
-2.9627
EPS:
-9.0964
Netto-Cashflow:
$-210.48M
1W Leistung:
-14.44%
1M Leistung:
-20.20%
6M Leistung:
+21.45%
1J Leistung:
+44.74%
1-Tages-Spanne:
$25.90
$28.50
1-Wochen-Bereich:
$25.70
$33.84
52-Wochen-Spanne:
$13.50
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Firmenname
Zenas Biopharma Inc
Sektor
Branche
Telefon
857-271-2954
Adresse
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
26.95 | 1.76B | 10.00M | -425.15M | -210.48M | -9.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | Eingeleitet | Wedbush | Outperform |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Zenas Biopharma Inc Aktie (ZBIO) Neueste Nachrichten
Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn? - AlphaStreet
Why Is Zenas BioPharma (ZBIO) Filing More Than $240 Million In Shelves? - Yahoo Finance
Zenas BioPharma to present obexelimab IgG4-RD trial data By Investing.com - Investing.com Nigeria
Zenas BioPharma to present obexelimab IgG4-RD trial data - Investing.com
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026 - The Manila Times
Zenas Biopharma Announces Upcoming Presentations Of Obexelimab Data In Igg4-Related Disease At The Igg4ward! 6Th International Symposium On Igg4-Related Disease And Acr Convergence 2026 - TradingView
Zenas BioPharma Announces Upcoming Presentations of - GlobeNewswire
Zenas BioPharma Grants Stock Options and RSUs to Newly Hired Employees as Inducement Awards - Quiver Quantitative
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Zenas BioPharma, Inc. (ZBIO): Analyst Ratings Suggest A 47% Upside In Biotech Investment - DirectorsTalk Interviews
New Zenas hires receive stock awards that vest over four years - Stock Titan
Zenas (ZBIO) Stock Analysis: -1.08% Loss — Key Levels 2026-09-17Key Reversal Day - siam.in
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Zenas BioPharma Files For Offering Of Up To 7.0 Million Shares Of Common Stock By The Selling StockholderSEC Filing - TradingView
Wellington Management Group LLP Adds 4,972,315 Shares of Zenas B - GuruFocus
ZBIO: Obexelimab nears FDA review with strong market potential and pivotal data readouts ahead - TradingView
Zenas BioPharma at Citi summit: pipeline bets and cash runway By Investing.com - Investing.com India
A 10% slice of Zenas BioPharma (NASDAQ: ZBIO) sits with one investment group - Stock Titan
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event - GlobeNewswire
InnoCare reports 10.4% passive Zenas BioPharma stake | ZBIO SEC FilingForm SCHEDULE 13G/A - Stock Titan
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences - Yahoo Finance
Director at Zenas BioPharma (ZBIO) granted 37,000 options - Stock Titan
Zenas BioPharma (ZBIO) Dips 1.69% to $31.77 as Shares Test Key Support ZoneRectangle Pattern - dars.gov.et
Enavate Sciences GP, LLC Reduces Zenas BioPharma Inc (ZBIO) Stak - GuruFocus
Zenas (ZBIO) Levels: Advances 2.12% to $32.29 in the Latest Reading; Levels: the Price Remains Bounded by the Supplied Support and Resistance at the CloseGap and Go - siam.in
Zenas BioPharma (ZBIO) Is Up 9.4% After Wider Losses And Board AdditionHas The Bull Case Changed? - simplywall.st
Zenas BioPharma (ZBIO) holder sells 673,755 shares in open-market trade - Stock Titan
Zenas BioPharma (ZBIO) affiliate plans August 2026 share sale - Stock Titan
New Zenas BioPharma hires receive stock awards vesting through 2030 - Stock Titan
HC Wainwright Predicts Higher Earnings for Zenas BioPharma - MarketBeat
SR One's stake in Zenas BioPharma (ZBIO) drops over 1 point without selling - Stock Titan
Morgan Stanley Maintains Zenas BioPharma(ZBIO.US) With Hold Rating, Raises Target Price to $32 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
ZBIO Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost Discipline for Clinical-Stage BiotechDividend Growth Analysis - vinanet.vn
Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush - MarketBeat
Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership ChangesWhat's Changed - simplywall.st
ZBIO SWOT Analysis: Financial Challenges and Strategic Opportuni - GuruFocus
Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results - MarketBeat
Zenas BioPharma Releases Q2 2026 Financial Results - AlphaStreet
Zenas BioPharma, Inc. Announces Chief Financial Officer Changes, Effective September 30, 2026 - marketscreener.com
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings - MarketBeat
Zenas BioPharma grants inducement awards to new hires - scanx.trade
Zenas BioPharma Q2 Results: EPS Misses, Sales Fall 95% - scanx.trade
Zenas BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Zenas Biopharma Inc For: 13 August By Investing.com - Investing.com Canada
Zenas BioPharma's Q2 Net Loss Widens; CFO to Step Down - marketscreener.com
Earnings Flash (ZBIO) Zenas BioPharma Posts Q2 Loss $1.77 a Share, vs. FactSet Est of $1.12 Loss - marketscreener.com
Zenas BioPharma, Inc. 2026: Revenue $1M, Net income ($111.46M), EPS ($1.77) — 10-Q Summary - TradingView
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Finanzdaten der Zenas Biopharma Inc-Aktie (ZBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):